

# Clinical trials of succinobucol

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 post myocardial infarction

Trial	Treatments	Patients	Trials design and methods
<b>succinobucol vs placebo</b>			
<a href="#">ARISE , 2007</a> [NCT00066898] n=3078/3066 follow-up: 24 months mean	succinobucol (300 mg/day) versus placebo	high-risk patients with recent acute coronary syndrome	Parallel groups Double blind canada, US, UK, South Africa

More details and results :

- antioxydants for post myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q424>

## References

### ARISE, 2007:

Tardif American College of Cardiology Annual Scientific Session, New Orleans, LA, March 2007 [0]

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:1761-8 [[18502300](#)] [10.1016/S0140-6736\(08\)60763-1](https://doi.org/10.1016/S0140-6736(08)60763-1)

## 2 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>succinobucol vs placebo</b>			
<a href="#">ARISE , 2008</a> [NCT00066898] n=3078/3066 follow-up: 24 mo (range 12-36 mo)	succinobucol 300 mg once daily versus placebo	patients with recent (14-365 days) acute coronary syndromes already managed with conventional treatments	Parallel groups double blind Canada, US, UK, South Africa

More details and results :

- antioxydants for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q131>

## References

### ARISE, 2008:

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:1761-8 [[18502300](#)]

## 3 post acute coronary syndromes

Trial	Treatments	Patients	Trials design and methods
<b>succinobucol vs placebo</b>			
<a href="#">ARISE , 2007</a> [NCT00066898] n=3078/3066 follow-up: 24 months mean	succinobucol (300 mg/day) versus placebo	high-risk patients with recent acute coronary syndrome	Parallel groups Double blind canada, US, UK, South Africa

More details and results :

- antioxydants for post acute coronary syndromes in all type of patients at <http://www.trialresultscenter.org/go-Q423>

## References

### ARISE, 2007:

Tardif American College of Cardiology Annual Scientific Session, New Orleans, LA, March 2007 [0]

Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L'Allier PL, Pfeffer MA Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:1761-8 [[18502300](#)] [10.1016/S0140-6736\(08\)60763-1](#)